SEEL Insider Trading Activity and SEC Form 4 Filings
SEEL insider trading summary
No open-market insider purchases or sales of Seelos Therapeutics, Inc. (SEEL) have been reported on SEC Form 4 in the past 12 months.
Latest SEEL insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 1, 2023 | Raj Mehra | See Remarks | Buy | $100K (75,757 @ $1.32) |
| Nov 30, 2023 | Michael Joseph Golembiewski | Chief Financial Officer | Buy | $100K (83,000 @ $1.21) |
| Jun 1, 2022 | Daniel J. O'Connor | Director | Buy | $10K (16,000 @ $0.61) |
| May 26, 2022 | Margaret Dalesandro | Director | Buy | $21K (35,000 @ $0.60) |
| Mar 31, 2022 | Raj Mehra | See Remarks | Buy | $57K (66,667 @ $0.85) |
| Feb 13, 2020 | Raj Mehra | See Remarks | Buy | $100K (133,333 @ $0.75) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.